The European Medicines Agency backed the use of Novo Nordisk's popular drug Wegovy to help ease heart failure in people with ...

U.S. telehealth company Hims & Hers Health on Wednesday said it will sell compounded versions of Novo Nordisk's popular ...

Nearly 4.4 million adult New Yorkers, or 30%, have obesity, but access to weight-loss medications varies based on a variety ...

People taking the experimental drug amycretin were found to lose almost twice as much weight over a 12-week period as the ...

Medicare may cover Wegovy for adults with cardiovascular disease and either obesity or overweight. Learn more about Medicare ...

A new study found that people taking Wegovy during the pandemic were 33 percent less likely to die of COVID-19.

So here are some items of interest. Have a great day, everyone. … Hims & Hers Health plans to sell compounded versions of Novo Nordisk’s popular weight loss drug Wegovy to patients in certain ...

The craze for new drugs in the GLP-1 (Glucagon-like peptide 1) and GIP (Gastric inhibitory polypeptide) analog class, better ...

A slow-release form of semaglutide could allow people who use Wegovy or Ozempic to get shots once a month, instead of the ...

As a health journalist, I’m doing my best to keep up with all things weight loss drugs, but with headlines rolling in every ...

Ozempic maker Novo Nordisk’s highly anticipated new obesity pill, Amycretin, shows the potential for much greater and faster ...

A recent study estimated that Wegovy’s label expansion beyond obesity could push Medicare spending to $145 billion annually, ...